These models could include transgenic models such as the MMTV-PyVmT and MMTV-neu lines, MIND models involving additional breast cancer cell lines and patient-derived xenograft models2 to address questions on the evolution of breast cancer subtype, effects of CCR2 and MET signaling in cancer progression over time, effects of CCR2 and MET inhibitors on breast cancer subtype and immune response in early stage breast cancer progression. This evidence concerns the gene CCR2 and breast carcinoma.